Xeris Pharmaceuticals Inc (XERS) — Cash Flow-to-Debt Ratio
Xeris Pharmaceuticals Inc (XERS) has a Cash Flow-to-Debt Ratio of 0.03x as of March 2026, meaning its operating cash flow of $9.87 Million could theoretically repay 0% of its total liabilities ($379.00 Million) in one year. Explore Xeris Pharmaceuticals Inc (XERS) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xeris Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Xeris Pharmaceuticals Inc across 10 annual periods. Also explore XERS asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Xeris Pharmaceuticals Inc (2016–2025)
Year-by-year debt coverage analysis for Xeris Pharmaceuticals Inc. For market capitalisation and broader financial context, see XERS company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | $28.63 Million | $369.84 Million | ▲ +173.8% |
| 2024 | -0.10x | $-36.98 Million | $352.68 Million | ▲ +26.5% |
| 2023 | -0.14x | $-47.02 Million | $329.38 Million | ▲ +58.5% |
| 2022 | -0.34x | $-102.89 Million | $299.33 Million | ▲ +24.8% |
| 2021 | -0.46x | $-95.53 Million | $209.13 Million | ▲ +46.4% |
| 2020 | -0.85x | $-80.56 Million | $94.55 Million | ▲ +22.8% |
| 2019 | -1.10x | $-104.35 Million | $94.55 Million | ▲ +12.5% |
| 2018 | -1.26x | $-56.28 Million | $44.62 Million | ▼ -425.9% |
| 2017 | -0.24x | $-24.66 Million | $102.83 Million | ▲ +2.4% |
| 2016 | -0.25x | $-16.09 Million | $65.47 Million | — |